Ftse Mib
32.856,40
0,59%
DAX
18.044,10
0,13%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,00%
Bitcoin
65.755,96
-1,33%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Iovance Biotherapeutics Inc (IOVA) Iovance Biotherapeutics Inc (IOVA) Notizie

Iovance Biotherapeutics Inc

IOVA
8,16
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 13:40:14
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
14/6/202400:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/6/202423:15EDGAR2Form 8-K - Current report
06/6/202402:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202402:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202402:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202414:01EDGAR2Form 8-K - Current report
24/5/202422:01GLOBEIovance Biotherapeutics to Present at Upcoming Conferences..
23/5/202423:00GLOBEIovance Biotherapeutics Announces Clinical Data in Frontline..
17/5/202423:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
17/5/202423:15GLOBEIovance Biotherapeutics Reports Inducement Grants under..
09/5/202423:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202422:06EDGAR2Form 8-K - Current report
09/5/202422:01GLOBEIovance Biotherapeutics Reports First Quarter 2024 Financial..
01/5/202412:01GLOBEIovance Biotherapeutics to Host First Quarter 2024 Financial..
30/4/202412:01GLOBEIovance Biotherapeutics to Present at Upcoming Conferences
24/4/202422:01GLOBEIovance Biotherapeutics to Present Clinical and..
19/4/202423:15GLOBEIovance Biotherapeutics Reports Inducement Grants under..
22/3/202422:30GLOBEIovance Biotherapeutics Reports Inducement Grants under..
07/3/202400:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202414:00EDGAR2Form 8-K - Current report
04/3/202412:30GLOBEIovance Biotherapeutics Announces FDA has Lifted Clinical..
01/3/202423:00GLOBEIovance Biotherapeutics to Present at Upcoming Conferences
29/2/202413:30EDGAR2Form 8-K - Current report
28/2/202422:05EDGAR2Form 8-K - Current report
28/2/202422:01GLOBEIovance Biotherapeutics Reports Fourth Quarter and Full Year..
22/2/202422:53EDGAR2Form 8-K - Current report
22/2/202414:45GLOBEIovance Biotherapeutics to Host Fourth Quarter and Full-Year..
21/2/202422:44EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/2/202423:23EDGAR2Form 8-K - Current report
20/2/202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202412:30GLOBEIovance Biotherapeutics, Inc. Announces Pricing of $211..
20/2/202412:03EDGAR2Form 8-K - Current report
16/2/202423:30GLOBEIovance Biotherapeutics Reports Inducement Grants under..
16/2/202421:38GLOBEIovance Biotherapeutics to Host Conference Call and Webcast..
16/2/202421:19GLOBEIovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA..
14/2/202412:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
19/1/202423:15GLOBEIovance Biotherapeutics Reports Inducement Grants under..
19/1/202400:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202400:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202400:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202423:03EDGAR2Form 8-K - Current report
28/12/202313:27IHMARKETNEWSWall Street Highlights: Amazon to Introduce Ads on Prime..
27/12/202323:00EDGAR2Form 8-K - Current report
Apertura: Min: Max:
Chiusura: 8,16

La tua Cronologia

NASDAQ
IOVA
Iovance Biotherapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network